New liposomal chemotherapy drug shows promise in early trial for advanced cancers
NCT ID NCT04047251
First seen Nov 01, 2025 · Last updated May 20, 2026 · Updated 32 times
Summary
This early-phase study is testing a new form of the chemotherapy drug topotecan, wrapped in a liposome (a tiny fat bubble), to see if it is safe and what dose works best. About 96 adults with advanced solid tumors (including ovarian, cervical, sarcoma, and certain lung and skin cancers) that have not responded to standard treatments will receive FF-10850. The main goals are to find the highest safe dose and to understand side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Dana Farber Cancer Institute (DFCI)
Boston, Massachusetts, 02215, United States
-
HonorHealth
Scottsdale, Arizona, 85258, United States
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Ohio State University Wexner Medical Center
Columbus, Ohio, 43221, United States
-
Sarah Cannon Research Institute at HealthONE
Denver, Colorado, 80218, United States
-
University of Wisconsin Clinical Science Center
Madison, Wisconsin, 53792, United States
Conditions
Explore the condition pages connected to this study.